H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Theravance Biopharma (NASDAQ:TBPH) on Monday, setting a price target of $32, which is approximately 48.01% above the present share price of $21.62.
Tsao expects Theravance Biopharma to post earnings per share (EPS) of -$1.40 for the third quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Theravance Biopharma, with an average price target of $34.6.
The analysts price targets range from a high of $42 to a low of $29.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $19.86 million and a net profit of -$72.48 million. The company's market cap is $1.36 billion.
According to TipRanks.com, H.C. Wainwright analyst Douglas Tsao is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.1% and a 49.15% success rate.
Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.